2023年第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日~6日盛大召开。近期，ASCO官网已公布会议日程和摘要题目。
【肿瘤资讯】整理了口头摘要专场（Oral Abstract Session）、LBA专场（Late-Breaking Abstract Session）、临床科学研讨会（Clinical Science Symposium）、壁报交流专场（Poster Discussion Session）的妇科肿瘤研究，与读者分享。
口头摘要专场- 妇科肿瘤
摘要号：5500
KEYNOTE-826: 帕博利珠单抗+化疗vs安慰剂+化疗一线治疗持续性、复发性或转移性宫颈癌的随机、双盲、3期研究的最终总生存期结果
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
讲者： Bradley J. Monk, MD | Division of Gynecological Oncology, HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix and Creighton University School of Medicine
摘要号：5501
标准放化疗( RTCT )前纳武利尤单抗+伊匹木单抗治疗方案对宫颈鳞状细胞癌FIGO IB3-IVA期患者的原位免疫影响：COLIBRI试验,一项GINECO研究
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study
讲者：Isabelle Laure Ray-Coquard, MD, PhD | Centre Léon Bérard, University Claude Bernard Lyon 1
摘要号：5502
Triapine（T）联合顺铂放化疗（CRT）治疗局部晚期宫颈癌和阴道癌：结果来自NRG-GY 006，一项III期随机试验
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
讲者：Charles A. Leath, MD, MSPH | O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine
摘要号：5503
Dostarlimab治疗原发性晚期或复发性(A/R )子宫内膜癌( EC )：RUBY试验( ENGOT-EN6-NSGO/GOG-3031/RUBY)的盲法独立中心审查( BICR )结果
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
讲者：Matthew A. Powell, MD | National Cancer Institute sponsored NRG Oncology, Washington University School of Medicine
摘要号：5504
在ENGOT-EN6/GOG3031/RUBY试验中，与卡铂/紫杉醇相比，接受dostarlimab联合CP治疗的患者在原发性晚期或复发性子宫内膜癌（pA/rEC）中的患者报告结局（PRO）
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial
讲者：Mansoor Raza Mirza, MD | Rigshospitalet, Copenhagen University Hospital, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit
摘要号：5516
卡瑞利珠单抗联合阿帕替尼治疗至少1次系统治疗失败的晚期或复发性子宫内膜癌患者：一项单臂Ⅱ期试验
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial
讲者：中国上海，复旦大学附属肿瘤医院 田文娟，MD, PhD
摘要号：5505
每周紫杉醇±ofranergene obadenovec (VB-111)治疗铂类耐药卵巢癌(OVAL Study / GOG 3018)的随机对照Ⅲ期试验
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018)
讲者：Rebecca Christian Arend, MD | University of Alabama at Birmingham
摘要号：LBA5506
度伐利尤单抗联合紫杉醇/卡铂 （PC）和贝伐珠单抗，随后对新诊断的肿瘤BRCA1/2未发生突变（non-tBRCAm）晚期卵巢癌（AOC）患者进行度伐利尤单抗，贝伐珠单抗和奥拉帕利维持治疗：来自随机、安慰剂( pbo )对照的Ⅲ期DUO - O试验的结果
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
讲者：Philipp Harter, MD, PhD | Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, and AGO
摘要号：5508
Luveltamab tazevibulin(STRO-002),一种抗叶酸受体α(FolRα)抗体药物偶联物(ADC),在FolRα表达广泛的复发性上皮性卵巢癌(OC)患者中的安全性和疗效: STRO-002-GM1 I期剂量扩展队列研究更新
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort
讲者：Ana Oaknin, MD, PhD | Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital
LBA专场- LBA5507研究的介绍和讨论
摘要号：LBA5507
III期MIRASOL（GOG 3045/ENGOT-ov 55）研究：mirvetuximab soravtansine vs.铂类耐药、晚期高级别上皮性卵巢癌、原发性腹膜癌或输卵管癌中高叶酸受体α表达的研究者化疗选择的初始报告
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
讲者：Kathleen N. Moore, MD, MS | Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center
临床科学研讨会专场-利刃出鞘：妇科癌症的手术治疗
摘要号：5509
卵巢癌腹腔热灌注化疗Ⅲ期OVHIPEC-1试验随访10年的最终生存分析
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up
讲者：Lot Aronson, MD | The Netherlands Cancer Institute - Antoni van Leeuwenhoek
摘要号：5510
铂类敏感复发性上皮性卵巢癌的腹腔热灌注化疗：CHIPOR 随机 III 期试验
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial
讲者：Jean-Marc Classe, MD, PhD | Institut de Cancérologie Ouest
摘要号：LBA5511
一项在低风险早期宫颈癌（LRESCC）患者中比较根治性子宫切除术和盆腔淋巴结清扫术（RH）与单纯子宫切除术和盆腔淋巴结清扫术（SH）的国际随机III期试验：由加拿大癌症试验组（CCTG CX.5-SHAPE）牵头的妇科癌症组间研究
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE)
讲者：Marie Plante | Division of Gynecologic Oncology, Université Laval, CHU de Quebec
壁报交流专场-妇科肿瘤
摘要号：5512 | Poster Bd #: 207
吉西他滨联合或不联合ATR抑制剂berzosertib治疗铂类耐药卵巢癌的随机II期研究：最终总生存期（OS）和生物标志物分析
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses
讲者：Panagiotis A. Konstantinopoulos, MD | Dana-Farber Cancer Institute
摘要号：5513 | Poster Bd #: 208
在一项WEE1抑制剂azenosertib (ZN-c3)联合化疗(CT)治疗铂类耐药或难治性(R/R )上皮性卵巢癌、腹膜癌或输卵管癌( EOC )的1b期剂量递增研究中，cyclin E1表达与临床结局的相关性
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)
讲者：Joyce F. Liu, MD | Department of Medical Oncology, Dana-Farber Cancer Institute
摘要号：5514 | Poster Bd #: 209
LACOG 1018：一项针对ER/PR阳性的高级别浆液性或子宫内膜样卵巢癌、输卵管癌或腹膜癌患者二线化疗后哌柏西利联合来曲唑的Ⅱ期试验
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018
讲者：Andreia Cristina De Melo, MD | Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Brazilian Gynecologic Oncology Group (EVA), Brazil; Division of Clinical Research and Technological Development- Brazilian National Cancer Institute (INCA)
摘要号：5515 | Poster Bd #: 210
ENGOT-ov60/GOG-3052/RAMP 201的初始疗效和安全性结果：一项avutometinib（VS-6766）± defactinib治疗复发性低级别浆液性卵巢癌（LGSOC）的II期研究
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
讲者：Susana N. Banerjee, PhD, FRCP, MA, MBBS | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI)
摘要号：5517 | Poster Bd #: 211
在罕见肿瘤中双重抗CTLA-4和抗PD-1阻断(DART)的II期篮子试验SWOG S1609：外阴癌
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers
讲者：Young Kwang Chae, MD, MBA | Northwestern University
摘要号：5519 | Poster Bd #: 213
在局部晚期宫颈癌（LACVCa）患者中预先施用和共同施用纳武利尤单抗（Nivo），并同步放化疗（CCRT）随后Nivo维持治疗的疗效和最终安全分析：GOTIC-018I期试验的结果
Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018
讲者：Kazuto Nakamura, MD, PhD | Department of Gynecology, Gunma Prefectural Cancer Center
摘要号：5520 | Poster Bd #: 214
新辅助卡瑞利珠单抗联合化疗治疗局部晚期宫颈癌（NACI研究）：一项前瞻性、单臂、II期试验
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial
讲者：中国湖北省武汉市，华中科技大学同济医学院附属同济医院 孙朝阳
摘要号：5528 | Poster Bd #: 215
晚期宫颈癌治疗：来自在线治疗决策工具的当代专家和医疗保健专业推荐的比较
Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool
讲者：Jerfiz Constanzo, PhD, MBA | Clinical Care Options
摘要号：5521 | Poster Bd #: 216
复发性卵巢癌（ROC）患者中尼拉帕利维持治疗的毒性特征和患者/医生之间的意见分歧：来自NIQOLE真实生活研究-GINECO研究的经验教训
Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study
讲者：Florence Joly, MD, PhD | Department of Medical Oncology, Centre François Baclesse
摘要号：5522 | Poster Bd #: 217
正常风险卵巢筛查研究（NROSS）：该研究21年来的结果更新
The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update
讲者：Chae Young Han, Ph.D | The UT MD Anderson Cancer Center
摘要号：5523 | Poster Bd #: 218
Covid-19大流行对美国妇科恶性肿瘤患者就诊模式和临床结局的影响
The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States
讲者：Adrian Kohut, MD | City of Hope National Comprehensive Cancer Center
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/search?q=&filters=%7B%22track%22:%5B%7B%22key%22:%22Gynecologic%20Cancer%22%7D%5D,%22sessionType%22:%5B%7B%22key%22:%22Education%20Session%22%7D,%7B%22key%22:%22Oral%20Abstract%20Session%22%7D,%7B%22key%22:%22Case-Based%20Panel%22%7D,%7B%22key%22:%22Clinical%20Science%20Symposium%22%7D,%7B%22key%22:%22Poster%20Discussion%20Session%22%7D,%7B%22key%22:%22Poster%20Session%22%7D,%7B%22key%22:%22Ticketed%20Session%22%7D%5D%7D
排版编辑：肿瘤资讯-饶运双
苏公网安备32059002004080号
